Low incidence of renal impairment observed in tenofovir-treated patients

E. Paul O'Donnell, Kimberly K. Scarsi, Kristin M. Darin, Lana Gerzenshtein, Michael J. Postelnick, Frank J. Palella

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: To compare the incidence of renal impairment in HIV-infected patients exposed versus unexposed to tenofovir and to characterize risk factors associated with renal impairment. Methods: We undertook a retrospective cohort and nested case-control study of 514 Northwestern University HIV Outpatient Study participants who received antiretroviral therapy (ART) between 1 August 2001 and 31 July 2007. Renal impairment was defined as meeting at least one of two validated criteria based on serum creatinine, calculated glomerular filtration rate and creatinine clearance. Multivariable analysis was performed to identify risk factors for renal impairment. Results: Renal impairment occurred in 14% (n=72) of the cohort and was not correlated with exposure to tenofovir in univariate analyses. In multivariable analysis, more advanced age [odds ratio (OR)=1.04, P=0.02], diabetes (OR=3.6, P,0.01), decreased weight (OR=0.97, P=0.02) and endpoint CD4 ≤200 cells/mm3 (OR=2.5, P=0.03) were positive predictors of renal impairment; tenofovir exposure (OR=0.41, P=0.01) was negatively correlated with renal impairment. Conclusions: Tenofovir-containing ART was associated with less renal impairment than ART without tenofovir in a patient cohort with a high incidence of renal impairment. Chronic co-morbid conditions known to be associated with renal impairment should be excluded prior to attributing renal impairment to tenofovir.

Original languageEnglish (US)
Article numberdkr039
Pages (from-to)1120-1126
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume66
Issue number5
DOIs
StatePublished - May 1 2011

Fingerprint

Tenofovir
Kidney
Incidence
Odds Ratio
Creatinine
HIV

Keywords

  • Antiretroviral therapy
  • HIV/AIDS
  • Nephrotoxicity
  • Risk factors

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

O'Donnell, E. P., Scarsi, K. K., Darin, K. M., Gerzenshtein, L., Postelnick, M. J., & Palella, F. J. (2011). Low incidence of renal impairment observed in tenofovir-treated patients. Journal of Antimicrobial Chemotherapy, 66(5), 1120-1126. [dkr039]. https://doi.org/10.1093/jac/dkr039

Low incidence of renal impairment observed in tenofovir-treated patients. / O'Donnell, E. Paul; Scarsi, Kimberly K.; Darin, Kristin M.; Gerzenshtein, Lana; Postelnick, Michael J.; Palella, Frank J.

In: Journal of Antimicrobial Chemotherapy, Vol. 66, No. 5, dkr039, 01.05.2011, p. 1120-1126.

Research output: Contribution to journalArticle

O'Donnell, EP, Scarsi, KK, Darin, KM, Gerzenshtein, L, Postelnick, MJ & Palella, FJ 2011, 'Low incidence of renal impairment observed in tenofovir-treated patients', Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, dkr039, pp. 1120-1126. https://doi.org/10.1093/jac/dkr039
O'Donnell EP, Scarsi KK, Darin KM, Gerzenshtein L, Postelnick MJ, Palella FJ. Low incidence of renal impairment observed in tenofovir-treated patients. Journal of Antimicrobial Chemotherapy. 2011 May 1;66(5):1120-1126. dkr039. https://doi.org/10.1093/jac/dkr039
O'Donnell, E. Paul ; Scarsi, Kimberly K. ; Darin, Kristin M. ; Gerzenshtein, Lana ; Postelnick, Michael J. ; Palella, Frank J. / Low incidence of renal impairment observed in tenofovir-treated patients. In: Journal of Antimicrobial Chemotherapy. 2011 ; Vol. 66, No. 5. pp. 1120-1126.
@article{e02924c7221743eaa97329fcdf8df251,
title = "Low incidence of renal impairment observed in tenofovir-treated patients",
abstract = "Objectives: To compare the incidence of renal impairment in HIV-infected patients exposed versus unexposed to tenofovir and to characterize risk factors associated with renal impairment. Methods: We undertook a retrospective cohort and nested case-control study of 514 Northwestern University HIV Outpatient Study participants who received antiretroviral therapy (ART) between 1 August 2001 and 31 July 2007. Renal impairment was defined as meeting at least one of two validated criteria based on serum creatinine, calculated glomerular filtration rate and creatinine clearance. Multivariable analysis was performed to identify risk factors for renal impairment. Results: Renal impairment occurred in 14{\%} (n=72) of the cohort and was not correlated with exposure to tenofovir in univariate analyses. In multivariable analysis, more advanced age [odds ratio (OR)=1.04, P=0.02], diabetes (OR=3.6, P,0.01), decreased weight (OR=0.97, P=0.02) and endpoint CD4 ≤200 cells/mm3 (OR=2.5, P=0.03) were positive predictors of renal impairment; tenofovir exposure (OR=0.41, P=0.01) was negatively correlated with renal impairment. Conclusions: Tenofovir-containing ART was associated with less renal impairment than ART without tenofovir in a patient cohort with a high incidence of renal impairment. Chronic co-morbid conditions known to be associated with renal impairment should be excluded prior to attributing renal impairment to tenofovir.",
keywords = "Antiretroviral therapy, HIV/AIDS, Nephrotoxicity, Risk factors",
author = "O'Donnell, {E. Paul} and Scarsi, {Kimberly K.} and Darin, {Kristin M.} and Lana Gerzenshtein and Postelnick, {Michael J.} and Palella, {Frank J.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1093/jac/dkr039",
language = "English (US)",
volume = "66",
pages = "1120--1126",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Low incidence of renal impairment observed in tenofovir-treated patients

AU - O'Donnell, E. Paul

AU - Scarsi, Kimberly K.

AU - Darin, Kristin M.

AU - Gerzenshtein, Lana

AU - Postelnick, Michael J.

AU - Palella, Frank J.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Objectives: To compare the incidence of renal impairment in HIV-infected patients exposed versus unexposed to tenofovir and to characterize risk factors associated with renal impairment. Methods: We undertook a retrospective cohort and nested case-control study of 514 Northwestern University HIV Outpatient Study participants who received antiretroviral therapy (ART) between 1 August 2001 and 31 July 2007. Renal impairment was defined as meeting at least one of two validated criteria based on serum creatinine, calculated glomerular filtration rate and creatinine clearance. Multivariable analysis was performed to identify risk factors for renal impairment. Results: Renal impairment occurred in 14% (n=72) of the cohort and was not correlated with exposure to tenofovir in univariate analyses. In multivariable analysis, more advanced age [odds ratio (OR)=1.04, P=0.02], diabetes (OR=3.6, P,0.01), decreased weight (OR=0.97, P=0.02) and endpoint CD4 ≤200 cells/mm3 (OR=2.5, P=0.03) were positive predictors of renal impairment; tenofovir exposure (OR=0.41, P=0.01) was negatively correlated with renal impairment. Conclusions: Tenofovir-containing ART was associated with less renal impairment than ART without tenofovir in a patient cohort with a high incidence of renal impairment. Chronic co-morbid conditions known to be associated with renal impairment should be excluded prior to attributing renal impairment to tenofovir.

AB - Objectives: To compare the incidence of renal impairment in HIV-infected patients exposed versus unexposed to tenofovir and to characterize risk factors associated with renal impairment. Methods: We undertook a retrospective cohort and nested case-control study of 514 Northwestern University HIV Outpatient Study participants who received antiretroviral therapy (ART) between 1 August 2001 and 31 July 2007. Renal impairment was defined as meeting at least one of two validated criteria based on serum creatinine, calculated glomerular filtration rate and creatinine clearance. Multivariable analysis was performed to identify risk factors for renal impairment. Results: Renal impairment occurred in 14% (n=72) of the cohort and was not correlated with exposure to tenofovir in univariate analyses. In multivariable analysis, more advanced age [odds ratio (OR)=1.04, P=0.02], diabetes (OR=3.6, P,0.01), decreased weight (OR=0.97, P=0.02) and endpoint CD4 ≤200 cells/mm3 (OR=2.5, P=0.03) were positive predictors of renal impairment; tenofovir exposure (OR=0.41, P=0.01) was negatively correlated with renal impairment. Conclusions: Tenofovir-containing ART was associated with less renal impairment than ART without tenofovir in a patient cohort with a high incidence of renal impairment. Chronic co-morbid conditions known to be associated with renal impairment should be excluded prior to attributing renal impairment to tenofovir.

KW - Antiretroviral therapy

KW - HIV/AIDS

KW - Nephrotoxicity

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=79954568575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954568575&partnerID=8YFLogxK

U2 - 10.1093/jac/dkr039

DO - 10.1093/jac/dkr039

M3 - Article

C2 - 21393145

AN - SCOPUS:79954568575

VL - 66

SP - 1120

EP - 1126

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 5

M1 - dkr039

ER -